FDA
-
-
-
-
-
-
-
FDA grants orphan drug status to Arcus' quemliclustat for pancreatic cancer
-
-
-
-
-
-
-
Arcus Biosciences Reports Second-Quarter 2024 Financial Results and Provides a Pipeline Update
-
-
-
-
-
-
-
Pre-Open Stock Movers 09/17: (CRVS) (ABCL) (BGNE) Higher; (PTGX) (GRTS) (X) Lower (more...)
-
-
-
-
-
-
-
Arcus Biosciences Appoints Biotech Industry Veteran, Andrew Perlman, M.D., Ph.D. and Gilead’s SVP of Research Biology, Michael Quigley, Ph.D. to Its Board of Directors
-
-
-
-
-
-
-
Arcus Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Updates
-
-
-
-
327,801 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

